Targeting Oxidative Stress in Chronic Beryllium Disease
Status:
Completed
Trial end date:
2015-03-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to understand if a drug called mesalamine helps to control
inflammation associated with chronic beryllium disease (CBD). We hypothesize that in CBD
subjects treated with prednisone, mesalamine treatment will enhance the immunosuppressive
effects of prednisone, and thus reduce the immune response to beryllium.